|Bid||115.40 x 500|
|Ask||116.12 x 500|
|Day's Range||110.98 - 116.13|
|52 Week Range||110.98 - 116.13|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.
Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis ...
This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: AveXis Inc. (NASDAQ: AVXS), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd, (NYSE: BHVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): All you have to do is sign up today for this free limited time offer by clicking the link below. On Tuesday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 941,320 shares, which was above their three months average volume of 884.73 thousand shares. The Company's shares have gained 88.91% over the previous three months and 181.89% in the past twelve months.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 1) ABIOMED, Inc. (NASDAQ: ABMD ) AveXis Inc (NASDAQ: AVXS ) (announced ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...
Basel, May 1 , 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") ...
NEW YORK, NY / ACCESSWIRE / April 27, 2018 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating AveXis, Inc. ("AveXis" or the "Company") (NASDAQ: AVXS) relating to the sale of the Company to affiliates of Novartis AG (NVS). The investigation focuses on whether AveXis and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company's stockholders by 1) failing to conduct a fair process, 2) whether and by how much this proposed transaction undervalues the Company and 3) whether all material financial information has been disclosed regarding the tender offer set to expire on May 14, 2018. Monteverde & Associates PC is a national class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.
NEW YORK , April 24, 2018 /PRNewswire/ -- ADT Inc. (ADT) Lifshitz & Miller announces investigation into possible securities law violations in connection with ADT's IPO. If you are an ADT investor, and ...
The following statement is being issued by Levi & Korsinsky, LLP:
BERWYN, Pa. , April 19, 2018 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of AveXis, Inc. ("AveXis" or the "Company") (NASDAQ: AVXS) ...
NEW YORK , April 19, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...